メニューを閉じる
Ja En
location Location
日野 真美
Patent Attorney and Registered Foreign Law Lawyer (New York) Partner

日野 真美 Mami Hino

Practice Areas

Career

Career

Education

Seton Hall University School of Law, USA 1999, J.D.

Kyoto University, Japan 1984, Bachelor of Pharmacy

 

Professional Experience

Abe Ikubo & Katayama (Counsel, 2004-2006; Partner, 2006-Present)

Baker & McKenzie, Tokyo (Associate, 2002-2004)

Pennie & Edmonds (Law Clerk, 1998-2000; Associate, 2000-2002)

Asahina Co., (Technical Advisor, 1990-1994; Associate, 1994-1996)

Fujisawa Pharmaceutical Company (Research Pharmacist 1984-1987)

 

Member of Intellectual Property Experts Committee at Japan Agency for Medical Research and Development (2015-Present)

Member of Intellectual Property Utilization Support Project Review Committee at Japan Science and Technology Agency (2010-2014)

 

 

Show More +

Memberships

Memberships

・ AIPPI Japan

・ Intellectual Property Owners Association

・ Tokyo IP American Inn of Court

 

Practice Areas

Practice Areas

Mami Hino has experience in representing the world’s leading technology companies for many years in disputes, litigation and transactions.  Mami’s practice emphasizes invalidity trials and resultant IP High Court appeals, cross-border infringement litigation, strategic patent prosecution, client counseling, and opinions.  She collaborates with a variety of clients from heavy machinery companies to consumer product companies, including chemical companies and pharmaceutical companies.

 

Due to her background as a registered pharmacist, Mami has extensive experience representing innovator pharmaceutical companies to protect their patents, such as filing patent term extension applications, defending their patents in invalidity trials and IP High Court appeals, filing preliminary injunction requests and/or patent infringement suits against generic drug companies.

 

Mami studied law at a U.S. law school (J.D.) and practiced as an attorney at a New York law firm that specializes in intellectual property.  She can provide foreign clients with Japanese IP advice by utilizing her understanding of the differences between foreign IP practice and Japanese IP practice.

 

Professional Admission

  • New York
  • Patent Attorney (admitted to practice intellectual property infringement litigation) in Japan
  • Foreign legal consultant in Japan
  • Pharmacist in Japan

 

 

Show More +

Publications

Books

Japanese Patent Litigation, Second Edition
Show More +

Articles

Japan IP High Court Clarified Scope of Patent Term Extension and Awarded Highest Ever Damages in Landmark Nalfurafine Case
Japan: Sawai’s Generic Drug is approved by the MHLW amid patent litigation with Bristol-Myers Squibb, but the Court orders preliminary injunction against Sawai soon after
Amgen v. Sanofi and Regeneron: Japan IP High Court overrules its own decision on validity of Amgen patent
Japan IP High Court’s first-ever decision allowing patent enforcement against infringing acts partially committed outside of Japan
Japan: Guidelines for a Transparent and Predictable SEP Licensing Negotiation
Practice Note, Patent Opposition Proceedings (Japan)
Checklists, Patent Opposition Proceedings: Flowchart (Japan)
JPO publishes the Status Report 2022
Discussion: Promotion of Diversity in the Intellectual Property Industry
Report of Diversity Survey in JPAA (2022)
Japan: Problem of Japan’s patent linkage system comes to the surface by a set of IP High Court decisions
Japan: PD-1/PD-L1 related patents: What are the co-inventorship requirements for an invention in the medicine field
Japan: MSD v Wyeth – The IP High Court upholds the validity of patent claims, finding inventive step in the functional limitation therein
Practice Note, Patent Invalidation Trials (Japan)
Checklist, Patent Invalidation Trials Flowchart (Japan)
A Japanese version Amicus Brief system will be introduced in spring 2022
Japan: The IP High Court has clarified that the Japanese Bolar exemption covers clinical testing for not only “generic” but also “innovator” drugs
Amicus Curiae Practice is Set to Make Its Statutory Debut in Japan
Show More +

Seminars

View All Seminars

Awards